Results from a pivotal trial for the Medtronic MiniMed 670G, the first hybrid closed-loop insulin delivery system, have been published in Diabetes Technology & Therapeutics, more than 4 months after the FDA approved the device. Touted by JDRF as the world's first "artificial pancreas," the MiniMed 670G will be available this spring, according to statements from Medtronic. The trial reports what had been announced already: the hybrid closed-loop (HCL) system was safe for home use, giving users increased time in their target range, with reductions in glycated hemoglobin (A1C) and less hypoglycemia or hyperglycemia than patients had at baseline. Notably, there were no severe events of hypoglycemia or any diabetic ketoacidosis in either patient group. The trial involved 30 adolescents, which included those 14 to 21 years of age, and 94 adults, 22 to 75 years of age, all with type 1 diabetes (T1D). Ten sites, 9 in the United States and 1 in Israel, took part in the pivotal trial.